Astria Map Editor 2.0 29
Dafna Lohan
The sci-fi/fantasy podcast Imaginary Worlds focused an episode on Asian futures, without Asians, with interviews with Astria Suparak, Jason Concepcion (host of the pop culture podcast X-Ray Vision), and David S. Roh (co-editor of the anthology Techno-Orientalism: Imagining Asia in Speculative Fiction, History, and Media).
Inspired by Fichte's concept of "Streben," this fashion editorial explores human emotions through seven scenes: surprise & ecstasy, reflection & meditation, loneliness, nostalgia, sadness, fear & dread, and rage & confusion. Each scene visually narrates the growth of feelings, culminating in a powerful climax. This journey uses vibrant colors and sensory elements to reflect the infinity of human moods.
Summer is the perfect time of year to cool down with a refreshing drink and enjoy the warm days. This summer, L'Officiel Austria has chosen the drink of the season, which you can enjoy with your loved ones at any time in Vienna's city centre.
The Sunnyside Community Hospital Association, the entity for Astria Sunnyside Hospital, reported an EBITDA of $807,357 in December. While positive, it was less than the nearly $1.5 million in EBITDA it had in May 2019. The association has maintained positive net earnings throughout the bankruptcy.
In the months leading up to the bankruptcy filing, the company had been making cuts, such as closing the rehabilitation unit at Astria Regional Medical Center and ending its long-standing support of the Central Washington Family Medicine residency.
Shortly after filing for bankruptcy, it started working with a new revenue cycle vendor. For several months the new vendor, Gaffey, focused on new revenue collections while the former one, which was later disclosed to be Cerner Corp., focused on getting older outstanding balances. In August, the new vendor, Gaffey, took over the entire revenue collection operation.
Astria Health did not comment on its current revenue collection efforts, but documents filed with the U.S. Bankruptcy Court shows that Astria Health has been able to recover much of what it was unable to collect when it filed for bankruptcy.
Astria Health and Cerner are still working to resolve their ongoing dispute in U.S. Bankruptcy Court. Astria Health is seeking damages from the revenue collection issue while Cerner claims that Astria Health owes money for services rendered before and after the bankruptcy filing.
In its reorganization plan, the organization projects continued growth in the next several years. In a consolidated income statement filed last fall, the organization anticipates annual net revenue to increase from $164.8 million in the 2020 fiscal year to $181.1 million by the 2025 fiscal year, a nearly 10% increase.
Astria Health declined to elaborate on how it came up with that growth forecast. Still, it said it expects further growth that would lead to additional job opportunities and increased medical providers.
In recent years, Astria Health has increased or relocated services to both hospitals. It opened a new behavioral health unit in Toppenish prior to the bankruptcy filing. It also moved services once offered in Yakima to Astria Sunnyside and nearby clinics.
This story is part of the Protecting and Promoting Local Journalism Initiative, a project supported by the Yakima Valley Community Foundation with financial, training and technological assistance from Microsoft Corp. In Yakima County, the initiative is a collaboration between the Yakima Herald-Republic, El Sol de Yakima and Radio KDNA, whose journalists maintain independent editorial control of the project.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.
Heartfelt thanks (and frankly, awe) are also owed to our art director Caroline Washington, a force whose singular energy and vision radiate off of every page of this issue. Thank you to Leo Brooks and Imran Siddiquee, whose quiet yet game-changing ideas have likewise deeply impacted the look and feel of these stories, both online and in print. To our brilliant and discerning editors Jasmine Weber, Kavita Rajanna, Yasmine Espert, and Shauna Swartz, tremendous thanks for your expertise and generative feedback. Each piece is stronger and all the more resonant for it.
To learn more, I recently talked to Klaus Fiala, editor in chief of Vienna-headquartered Forbes Austria, the German-language edition of Forbes. Austria is part of the Alps, a region including Switzerland, Italy and France that accounted for more than a quarter of global ski visits in 2022 and boasts leading ski equipment companies such as Fischer, Rossignol and Elan.
InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at edi...@investorplace.com.
Please submit your revised manuscript by Oct 23 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plo...@plos.org. When you're ready to submit your revision, log on to and select the 'Submissions Needing Revision' folder to locate your manuscript file.
Please include the following items when submitting your revised manuscript:
- A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
- A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
- An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: -guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at _medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.
I have read the journal's policy and the authors of this manuscript have the following competing interests: JC received honoraria and consultation fees from AstraZeneca, Merck, GSK, Sanofi, Genzyme, Takeda, CSL Behring, Octapharma, and Biogen. SB received advisory, speaker and committee fees or research funding from Astria, Canadian Blood Services, CSL Behring, Grifols, Ionis Pharmaceuticals, Kalvista Novartis, Octapharma, Pharvaris, Sanofi, and Takeda. SW received research funding, speaker and consultation fees from CAAIF, ALK Abello, Pfizer, Aimmune Schroeder Foundation, Sean Delaney foundation, GSK, Novartis, CSL Behring, Sanofi, Astrazaneca, Takeda, Teva, Medexus, Mylan, AbbVie, Miravohealth, Bausch Lomb, Avir Pharma and Covis. DWC received consultation and speaker fees from Takeda and CSL Behring. SS and AA have declared that no competing interests exist.
We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors.
Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.
3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.
The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
Reviewer #1: I write regarding PONE-D-23-25320 entitled "Clinical Outcomes of Immunoglobulin Treatment for Patients with Secondary Antibody Deficiency: Data from the Ontario Immunoglobulin Treatment Case Registry ".
An observational study evaluating immunoglobulin replacement therapy in patients with secondary antibody deficiency. A total of 141 patients were evaluated and especially their quality of life and infection rates were evaluated. Indeed, the use of IgRT in clinical practice is controversial in terms of cost effectiveness and indications. Therefore, I think that this article meets the unmet need on an important issue. I have a few suggestions.
b1e95dc632